Back to Search
Start Over
Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study.
- Source :
-
International journal of clinical oncology [Int J Clin Oncol] 2015 Aug; Vol. 20 (4), pp. 829-38. Date of Electronic Publication: 2014 Dec 26. - Publication Year :
- 2015
-
Abstract
- Background: Although we previously demonstrated that paclitaxel and carboplatin chemotherapy (TCchem) is associated with vascular toxicities, the underlying mechanisms remain unclear. Cisplatin is known to inhibit PPARα following microvascular damage to the kidneys. The primary aim of this study was to evaluate whether TCchem induces vascular endothelial dysfunction via systemic PPARα deficiency. In addition, human umbilical vein endothelial cells (HUVECs) were used to elucidate the mechanisms responsible for TCchem-induced vascular toxicities.<br />Methods: This study enrolled 45 gynecological cancer patients with normal lipid profiles who underwent surgical treatment followed by TCchem. The elevated triglyceride (TG) group included patients (n = 19) who exhibited hypertriglyceridemia during TCchem, and the stable TG group (n = 15) included patients with a normal TG level. Eleven patients exhibiting hypertriglyceridemia during TCchem were administered bezafibrate (fibrate group). Endothelial dysfunction was evaluated based on flow-mediated dilation (FMD) values and serum pentraxin-3 levels measured before TCchem and immediately after the final TCchem. HUVECs were used to elucidate the biological mechanisms underlying the endothelial dysfunction induced by TCchem.<br />Results: The administration of TCchem induced hypertriglyceridemia in 66 percent of the participants, and bezafibrate reduced the serum TG levels. Meanwhile, the decrease in flow-mediated dilatation (%FMD) induced by TCchem improved following treatment with bezafibrate. The serum pentraxin-3 level increased rapidly after TCchem and decreased following bezafibrate treatment. An in vitro examination demonstrated TCchem attenuated nitric oxide production and PPARα activity in HUVECs, which was partially improved by treatment with bezafibrate.<br />Conclusion: Bezafibrate prevents endothelial dysfunction induced by TCchem via TG-dependent and TG-independent mechanisms.
- Subjects :
- Adult
Aged
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Bezafibrate pharmacology
Carboplatin pharmacology
Carboplatin therapeutic use
Female
Genital Neoplasms, Female drug therapy
Humans
Middle Aged
Nitric Oxide biosynthesis
PPAR alpha antagonists & inhibitors
PPAR alpha metabolism
Paclitaxel pharmacology
Paclitaxel therapeutic use
Pilot Projects
Triglycerides blood
Umbilical Veins drug effects
Vascular Diseases chemically induced
Vasodilator Agents pharmacology
Antineoplastic Agents adverse effects
Bezafibrate therapeutic use
Carboplatin adverse effects
Endothelium, Vascular drug effects
Paclitaxel adverse effects
Vascular Diseases prevention & control
Vasodilator Agents therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1437-7772
- Volume :
- 20
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- International journal of clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 25539886
- Full Text :
- https://doi.org/10.1007/s10147-014-0779-y